SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950142-23-000265
Filing Date
2023-02-02
Accepted
2023-02-02 16:15:59
Documents
13
Period of Report
2023-02-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh230326994_8k.htm   iXBRL 8-K 27956
  Complete submission text file 0000950142-23-000265.txt   247154

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nrxp-20230202.xsd EX-101.SCH 3958
3 XBRL DEFINITION FILE nrxp-20230202_def.xml EX-101.DEF 26608
4 XBRL LABEL FILE nrxp-20230202_lab.xml EX-101.LAB 36687
5 XBRL PRESENTATION FILE nrxp-20230202_pre.xml EX-101.PRE 25232
7 EXTRACTED XBRL INSTANCE DOCUMENT eh230326994_8k_htm.xml XML 5562
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 23581103
SIC: 2834 Pharmaceutical Preparations